The fully linked HTML version of this article has now been published.
JCS ePress
online publication date 16 Sep 2003
doi: 10.1242/jcs.00712
Research Article
Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis
Anna M. Joy*,
Christian E. Beaudry,
Nhan L. Tran,
Francisco A. Ponce,
David R. Holz,
Tim Demuth,
and
Michael E. Berens
* Author for correspondence (e-mail: ajoy{at}tgen.org)
Glioma cells that migrate out of the main tumor mass into normal brain tissue contribute to the failure of most gliomas to respond to treatment. Treatments that target migratory glioma cells may enhance the therapeutic response. Multiple lines of evidence suggest that suppression of apoptosis accompanies activation of the migratory phenotype. Here, we determine whether migration and apoptosis are consistently linked in glioma cells and whether manipulation of migration influences cytotoxic therapy-induced apoptosis. Camptothecin and Trail-induced apoptosis were decreased 2-5-fold in actively migrating glioma cells relative to migration-restricted cells. Consistent with a mechanistic link between migration and apoptosis, the dose-response for stimulation of migration on laminin was inversely proportional to apoptosis induction. Treatment of glioma cells with migration inhibitors alone had little effect on basal rates of apoptosis and had little effect on Trail-induced or camptothecin-induced apoptosis in migration-restricted cells. By contrast, migration inhibitors increased camptothecin and Trail-induced apoptosis in actively migrating glioma cells. Migrating glioma cells have increased amounts of phosphorylated Akt and its downstream substrate glycogen synthase kinase-3 relative to migration restricted cells. Treatment of migrating cells with a specific inhibitor of phosphoinositide 3-kinase (PI3-K), LY294002, blocked the phosphorylation of Akt and increased the sensitivity to apoptosis. LY294002 had no effect on the migration of restricted cells. This suggests that migrating glioma cells activate the PI3-K survival pathway, protecting migrating cells from apoptosis. Taken together, these data provide support for a link between migration and apoptosis in glioma cells. In addition, evidence indicates that treatment with migration inhibitors, while not affecting apoptosis-induction in migration-restricted cells, can sensitize migrating glioma cells to cytotoxic agents.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Delamarre, S. Taboubi, S. Mathieu, C. Berenguer, V. Rigot, J.-C. Lissitzky, D. Figarella-Branger, L. Ouafik, and J. Luis
Expression of Integrin {alpha}6{beta}1 Enhances Tumorigenesis in Glioma Cells
Am. J. Pathol.,
August 1, 2009;
175(2):
844 - 855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Zong, C. C. Bastie, J. Xu, R. Fassler, K. P. Campbell, I. J. Kurland, and J. E. Pessin
Insulin Resistance in Striated Muscle-specific Integrin Receptor {beta}1-deficient Mice
J. Biol. Chem.,
February 13, 2009;
284(7):
4679 - 4688.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Liu, B. Tian, M. Gearing, S. Hunter, K. Ye, and Z. Mao
Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion
PNAS,
May 27, 2008;
105(21):
7570 - 7575.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Sakurai and N. Osumi
The Neurogenesis-Controlling Factor, Pax6, Inhibits Proliferation and Promotes Maturation in Murine Astrocytes
J. Neurosci.,
April 30, 2008;
28(18):
4604 - 4612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Wykosky, D. M. Gibo, C. Stanton, and W. Debinski
Interleukin-13 Receptor {alpha}2, EphA2, and Fos-Related Antigen 1 as Molecular Denominators of High-Grade Astrocytomas and Specific Targets for Combinatorial Therapy
Clin. Cancer Res.,
January 1, 2008;
14(1):
199 - 208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Wykosky, D. M. Gibo, and W. Debinski
A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells
Mol. Cancer Ther.,
December 1, 2007;
6(12):
3208 - 3218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Lefranc, V. Facchini, and R. Kiss
Proautophagic Drugs: A Novel Means to Combat Apoptosis-Resistant Cancers, with a Special Emphasis on Glioblastomas
Oncologist,
December 1, 2007;
12(12):
1395 - 1403.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, et al.
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Genes & Dev.,
November 1, 2007;
21(21):
2683 - 2710.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Demuth, L. B. Reavie, J. L. Rennert, M. Nakada, S. Nakada, D. B. Hoelzinger, C. E. Beaudry, A. N. Henrichs, E. M. Anderson, and M. E. Berens
MAP-ing glioma invasion: Mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival
Mol. Cancer Ther.,
April 1, 2007;
6(4):
1212 - 1222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sliwa, D. Markovic, K. Gabrusiewicz, M. Synowitz, R. Glass, M. Zawadzka, A. Wesolowska, H. Kettenmann, and B. Kaminska
The invasion promoting effect of microglia on glioblastoma cells is inhibited by cyclosporin A
Brain,
February 1, 2007;
130(2):
476 - 489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Lun, D. L. Senger, T. Alain, A. Oprea, K. Parato, D. Stojdl, B. Lichty, A. Power, R. N. Johnston, M. Hamilton, et al.
Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV{Delta}M51) on Multifocal and Invasive Gliomas.
J Natl Cancer Inst,
November 1, 2006;
98(21):
1546 - 1557.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nakada, J. A. Niska, N. L. Tran, W. S. McDonough, and M. E. Berens
EphB2/R-Ras Signaling Regulates Glioma Cell Adhesion, Growth, and Invasion
Am. J. Pathol.,
August 1, 2005;
167(2):
565 - 576.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Lefranc, J. Brotchi, and R. Kiss
Possible Future Issues in the Treatment of Glioblastomas: Special Emphasis on Cell Migration and the Resistance of Migrating Glioblastoma Cells to Apoptosis
J. Clin. Oncol.,
April 1, 2005;
23(10):
2411 - 2422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. L. Tran, W. S. McDonough, B. A. Savitch, T. F. Sawyer, J. A. Winkles, and M. E. Berens
The Tumor Necrosis Factor-like Weak Inducer of Apoptosis (TWEAK)-Fibroblast Growth Factor-inducible 14 (Fn14) Signaling System Regulates Glioma Cell Survival via NF{kappa}B Pathway Activation and BCL-XL/BCL-W Expression
J. Biol. Chem.,
February 4, 2005;
280(5):
3483 - 3492.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Shi, S. Bao, J. A. Maxwell, E. D. Reese, H. S. Friedman, D. D. Bigner, X.-F. Wang, and J. N. Rich
Secreted Protein Acidic, Rich in Cysteine (SPARC), Mediates Cellular Survival of Gliomas through AKT Activation
J. Biol. Chem.,
December 10, 2004;
279(50):
52200 - 52209.
[Abstract]
[Full Text]
[PDF]
|
|
|
© The Company of Biologists Ltd 2003
